Meliconi R, Senaldi G, Sturani C, Galavotti V, Facchini A, Gasbarrini G, Vergani D
I Patologia Medica, University of Bologna, Italy.
Clin Immunol Immunopathol. 1990 Oct;57(1):64-73. doi: 10.1016/0090-1229(90)90022-i.
Immune complexes have been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a chronic inflammatory disease of unknown etiology. Using newly developed techniques to measure complement fragments, we assessed whether complement activation occurs in IPF and its relationship to circulating immune complexes (CIC), disease severity, and prognosis. We measured the fragments C3d, C4d, and Ba of the common, classical, and alternative pathway, respectively, along with the components C3, C4, and Factor B and CIC, in 18 patients and 19 healthy subjects. The fragment to parent molecule ratios C3d/C3, C4d/C4, and Ba/Factor B were derived. Complement determinations were repeated in 14 of the patients on a second occasion separated by 8-33 months (median 17 months) from the first. All parameters were higher in patients than controls, and the difference between the two groups was significant for C3d, C4d/C4, C3, CIC (P less than 0.05) and for C4d and Ba (P less than 0.01). Fragment Ba was found to correlate with disease duration and indices of disease severity, i.e., positively with the dyspnoea score (Rs = 0.44, P less than 0.04), the physiological score (Rs = 0.50, P less than 0.02), the fibrosis score (Rs = 0.45, P less than 0.04), and a composite clinical, radiological, and physiological score (Rs = 0.48, P less than 0.03) and negatively with the forced vital capacity (Rs = -0.47, P less than 0.03). Ba was higher in those patients who deteriorated on follow-up analysis than those who improved or remained unchanged (P less than 0.04). These results show that conversion products of all complement pathways are increased in IPF and demonstrate classical pathway activation. They also show that the measurement of Ba might prove a useful laboratory test of disease severity in this condition.
免疫复合物与特发性肺纤维化(IPF)的发病机制有关,IPF是一种病因不明的慢性炎症性疾病。我们使用新开发的技术来测量补体片段,评估补体激活是否在IPF中发生及其与循环免疫复合物(CIC)、疾病严重程度和预后的关系。我们测量了18例患者和19名健康受试者中补体经典途径、替代途径和常见途径的片段C3d、C4d和Ba,以及补体成分C3、C4、因子B和CIC。得出片段与母体分子的比率C3d/C3、C4d/C4和Ba/因子B。14例患者在与第一次相隔8 - 33个月(中位数17个月)的第二次检查时重复进行补体测定。患者的所有参数均高于对照组,两组之间在C3d、C4d/C4、C3、CIC方面差异有统计学意义(P < 0.05),在C4d和Ba方面差异有高度统计学意义(P < 0.01)。发现片段Ba与疾病持续时间和疾病严重程度指标相关,即与呼吸困难评分呈正相关(Rs = 0.44,P < 0.04),与生理评分呈正相关(Rs = 0.50,P < 0.02),与纤维化评分呈正相关(Rs = 0.45,P < 0.04),与综合临床、放射学和生理评分呈正相关(Rs = 0.48,P < 0.03),与用力肺活量呈负相关(Rs = -0.47,P < 0.03)。随访分析中病情恶化的患者的Ba高于病情改善或无变化的患者(P < 0.04)。这些结果表明,IPF中所有补体途径的转化产物均增加,并显示出经典途径激活。它们还表明,在这种情况下,测量Ba可能是一种有用的疾病严重程度实验室检测方法。